Virpax Pharmaceuticals, Inc.

NasdaqCM:VRPX Stock Report

Market Cap: US$3.0m

Virpax Pharmaceuticals Balance Sheet Health

Financial Health criteria checks 3/6

Virpax Pharmaceuticals has a total shareholder equity of $-2.1M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $304.2K and $2.4M respectively.

Key information

0%

Debt to equity ratio

US$0

Debt

Interest coverage ration/a
CashUS$17.23k
Equity-US$2.05m
Total liabilitiesUS$2.36m
Total assetsUS$304.16k

Recent financial health updates

Recent updates

Virpax Pharmaceuticals GAAP EPS of -$0.50 misses by $0.06

Aug 15

Virpax: Targeting Pain At Its Source

Sep 04

Virpax Pharmaceuticals shares surge on Envelta IND update

Jun 21

Financial Position Analysis

Short Term Liabilities: VRPX has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.

Long Term Liabilities: VRPX has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.


Debt to Equity History and Analysis

Debt Level: VRPX is debt free.

Reducing Debt: VRPX's has negative shareholder equity, so we do not need to check if its debt has reduced over time.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: VRPX has sufficient cash runway for 0 months based on last reported free cash flow, but has since raised additional capital.

Forecast Cash Runway: VRPX is forecast to have sufficient cash runway for 0 months based on free cash flow estimates, but has since raised additional capital.


Discover healthy companies